Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures

   Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular
                              Surgery Procedures

--LeGoo® proprietary gel technology provides clear surgical field for
cardiothoracic and vascular surgeons without trauma to blood vessels--

PR Newswire

BRIDGEWATER, N.J., Jan. 29, 2013

BRIDGEWATER, N.J., Jan.29, 2013 /PRNewswire/ --Sanofi US announced the
commercial launch of LeGoo^®, a biopolymer gel that allows surgeons to
temporarily stop blood flow during surgery without the use of clamps, elastic
loops or other conventional occlusion devices, which may increase risk of
trauma to blood vessels. The atraumatic occlusion technique potentially
provides clear visualization with less clutter while maintaining vessel
integrity. The announcement was made in conjunction with this year's annual
Society of Thoracic Surgeons (STS) Meeting, which is being held in Los Angeles
this week.

To view the multimedia assets, please click:
http://www.multimedianewscenter.com/biosurgerylegoo/legoo-full-commercial-availability

As the first and only atraumatic intraluminal occlusion gel, LeGoo is injected
into a blood vessel and forms a plug that molds to the shape of the vessel,
stopping blood flow temporarily. The plug custom-adapts to the contour of each
individual blood vessel, delivering a truly sophisticated approach to surgical
procedures. Upon completion of the anastomosis, LeGoo is dissolved
spontaneously in about 15 minutes or by cooling the vessel directly through
ice application or cold saline infusion, which restores blood flow.

"LeGoo represents an elegantly simple and atraumatic solution to temporary
vessel occlusion," David H. Deaton, MD FACS, Chief, Vascular and Endovascular
Surgery, MedStar Georgetown University Hospital. "The fluid nature of LeGoo
adapts to any arterial anatomy irrespective of shape or calcific disease,
delivering a truly sophisticated and flexible approach to vascular anastomoses
and providing a clear surgical field. LeGoo is an innovative advance in
cardiovascular surgery."

LeGoo was approved in the United States in October 2011 for temporary
atraumatic occlusion of blood vessels up to 4mm in diameter below the neck.
The need for temporary atraumatic vascular occlusion and a bloodless field
exists in numerous surgical applications, though the current focus for LeGoo
is in cardiac and peripheral vascular surgery. It is CE-marked and has been
used in more than 3,000 procedures in Europe. In a randomized multicenter
study of 110 patients undergoing off-pump coronary artery bypass graft
surgery, LeGoo provided satisfactory hemostasis in a statistically significant
higher percentage of vessel grafts.

"LeGoo has the potential to change the paradigm of vascular and cardiovascular
surgical procedures through a completely new approach to a long-accepted
standard of care," said Anne Whitaker, President, North America
Pharmaceuticals. "The commercial launch of LeGoo is one of several innovations
Sanofi is launching in 2013 and proof of our commitment to finding new health
care solutions by putting patients first while also diversifying our
Biosurgery portfolio."

Sanofi acquired Pluromed, the company that invented LeGoo, in March 2012 to
add to its biosurgery portfolio and support its commitment to remain at the
forefront of innovative approaches to drug discovery and surgical device
development to help patients live longer, healthier lives.

About LeGoo
LeGoo^® is a thermo-sensitive biocompatible and non-toxic liquid gel that
forms a plug when injected into a blood vessel to temporarily stop blood flow.
The plug dissolves rapidly via cooling or spontaneously after several minutes.
Once dissolved, the plug cannot reform because the concentration is too low.
In a prospective, randomized study, LeGoo was shown to provide better
operating conditions than conventional occlusion techniques by limiting blood
flow into a surgical field without causing damage to the vessels. The study
also showed a reduction in the time required to perform an anastomosis for
beating heart surgery when using LeGoo. Time is critical to patient outcomes
in these types of surgical interventions.

Important Safety Information
LeGoo should only be used by physicians properly trained in vascular occlusion
techniques. LeGoo should not be used in patients with vascular anatomy or
blood flow that precludes cannula placement or proper injection and control of
LeGoo or in patients intolerant to vascular occlusion or where temporary
vascular occlusion would be contraindicated. Do not inject LeGoo into a vessel
that is not intended to be occluded. Always use the minimum volume of LeGoo
required to achieve satisfactory occlusion. LeGoo dissolves naturally and
re-application may be necessary to maintain temporary blood vessel occlusion.
Excessive or prolonged vessel occlusion may result in increased ischemic risks
to the patient. Adverse Events (AEs) in clinical studies with LeGoo are
consistent with anticipated AEs for patients undergoing cardiovascular
surgery. Additional safety and Adverse Event information for LeGoo are
described in the Instructions for Use (IFU).

About Sanofi Biosurgery
Sanofi Biosurgery is a global strategic business unit of Sanofi. It develops
and markets innovative, biologically based products for osteoarthritis relief,
adhesion prevention, cartilage repair, and severe burn treatment. Sanofi
Biosurgery's products include: Synvisc^®, Synvisc-One™ (hylan G-F 20),
Carticel^® (autologous cultured chondrocytes), MACI^® (Matrix-induced
Autologous Chondrocyte Implantation), Seprafilm^® and Epicel^® (cultured
epidermal autografts). Sanofi Biosurgery is committed to transforming disease
management through innovative medical interventions.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, rare diseases, consumer
healthcare, emerging markets and animal health. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi is the holding company of a consolidated group of subsidiaries and
operates in the United States as Sanofi US, also referred to as Sanofi-aventis
U.S. LLC. For more information on Sanofi US, please visit http://www.sanofi.us
or call 1-800-981-2491.

Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labeling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2011. Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.

------------------------------------------------------------------------------

Contacts:
Media Relations         Investor Relations
Sarah Connors      Kristen Galfetti
Tel.: 617.252.7639     Tel.: 1 908 981.5560
Sarah.Connors@sanofi.com  ir@sanofi.com

SOURCE Sanofi

Website: http://www.sanofi.us